Literature DB >> 26659332

The Ireland-Claisen rearrangement strategy towards the synthesis of the schizophrenia drug, (+)-asenapine.

Raghunath Reddy Anugu1, Prathama S Mainkar, Balasubramanian Sridhar, Srivari Chandrasekhar.   

Abstract

(±)-Asenapine, sold in the market as Saphris/Sycrest for the treatment of bipolar disorders, is synthesized in an optically pure form involving an Ireland-Claisen rearrangement as the key step. This approach allows access to all diastereomers.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26659332     DOI: 10.1039/c5ob02047f

Source DB:  PubMed          Journal:  Org Biomol Chem        ISSN: 1477-0520            Impact factor:   3.876


  5 in total

1.  Total Synthesis of Oxepin and Dihydrooxepin Containing Natural Products.

Authors:  Kevin Rafael Sokol; Thomas Magauer
Journal:  Synthesis (Stuttg)       Date:  2021-06-24       Impact factor: 3.157

2.  Decarboxylative Cross-Coupling: A Radical Tool in Medicinal Chemistry.

Authors:  Gabriele Laudadio; Maximilian D Palkowitz; Tamara El-Hayek Ewing; Phil S Baran
Journal:  ACS Med Chem Lett       Date:  2022-08-10       Impact factor: 4.632

3.  Radical Retrosynthesis.

Authors:  Joel M Smith; Stephen J Harwood; Phil S Baran
Journal:  Acc Chem Res       Date:  2018-08-02       Impact factor: 22.384

4.  Building C(sp3)-rich complexity by combining cycloaddition and C-C cross-coupling reactions.

Authors:  Tie-Gen Chen; Lisa M Barton; Yutong Lin; Jet Tsien; David Kossler; Iñaki Bastida; Shota Asai; Cheng Bi; Jason S Chen; Mingde Shan; Hui Fang; Francis G Fang; Hyeong-Wook Choi; Lynn Hawkins; Tian Qin; Phil S Baran
Journal:  Nature       Date:  2018-07-30       Impact factor: 49.962

Review 5.  Immunoendocrine Peripheral Effects Induced by Atypical Antipsychotics.

Authors:  Samantha Alvarez-Herrera; Raúl Escamilla; Oscar Medina-Contreras; Ricardo Saracco; Yvonne Flores; Gabriela Hurtado-Alvarado; José Luis Maldonado-García; Enrique Becerril-Villanueva; Gilberto Pérez-Sánchez; Lenin Pavón
Journal:  Front Endocrinol (Lausanne)       Date:  2020-04-21       Impact factor: 5.555

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.